Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18468564rdf:typepubmed:Citationlld:pubmed
pubmed-article:18468564lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:18468564lifeskim:mentionsumls-concept:C0035168lld:lifeskim
pubmed-article:18468564lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:18468564lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:18468564pubmed:issue9-10lld:pubmed
pubmed-article:18468564pubmed:dateCreated2008-5-12lld:pubmed
pubmed-article:18468564pubmed:abstractTextDeclining productivity with decreasing new molecular entity output combined with increased R&D spending is one of the key challenges for the entire pharmaceutical industry. In order to offset decreasing new molecular entity output, life-cycle management activities for established drugs become more and more important to maintain or even expand clinical indication and market opportunities. Life-cycle management covers a whole range of activities from strategic pricing to a next generation product launch. In this communication, we review how research organizations can contribute to successful life-cycle management strategies using phosphodiesterase 5 inhibitors as an example.lld:pubmed
pubmed-article:18468564pubmed:languageenglld:pubmed
pubmed-article:18468564pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18468564pubmed:citationSubsetIMlld:pubmed
pubmed-article:18468564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18468564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18468564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18468564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18468564pubmed:statusMEDLINElld:pubmed
pubmed-article:18468564pubmed:monthMaylld:pubmed
pubmed-article:18468564pubmed:issn1359-6446lld:pubmed
pubmed-article:18468564pubmed:authorpubmed-author:SandnerPeterPlld:pubmed
pubmed-article:18468564pubmed:authorpubmed-author:ZiegelbauerKa...lld:pubmed
pubmed-article:18468564pubmed:issnTypePrintlld:pubmed
pubmed-article:18468564pubmed:volume13lld:pubmed
pubmed-article:18468564pubmed:ownerNLMlld:pubmed
pubmed-article:18468564pubmed:authorsCompleteYlld:pubmed
pubmed-article:18468564pubmed:pagination457-63lld:pubmed
pubmed-article:18468564pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:meshHeadingpubmed-meshheading:18468564...lld:pubmed
pubmed-article:18468564pubmed:year2008lld:pubmed
pubmed-article:18468564pubmed:articleTitleProduct-related research: how research can contribute to successful life-cycle management.lld:pubmed
pubmed-article:18468564pubmed:affiliationBayer HealthCare AG, Global Drug Discovery, Germany. peter.sandner@bayerhealthcare.comlld:pubmed
pubmed-article:18468564pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18468564pubmed:publicationTypeReviewlld:pubmed